Lipid management: tools for getting to the goal.

作者: McKenney Jm

DOI:

关键词:

摘要: The treatment of hypercholesterolemia in the United States begins with recognition elevated low-density lipoprotein cholesterol (LDL-C) as primary target. An optimal LDL-C level has been defined < 100 mg/dL. first step lowering continues to be lifestyle modification, which includes a restriction saturated fat and cholesterol, increased physical activity, weight loss, if applicable. Approximately half all patients levels will ultimately need lipid-lowering drug achieve goals. preferred for first-line most is statin; bile acid resin or niacin can used who cannot tolerate statins are not candidates stain therapy. Combination therapy an option, several combinations showing efficacy (statin plus resin, resin) both triglycerides fibrate, statin niacin, niacin). Successful lipid management treating reach goal level, non-high-density applicable, managing other risk factors coronary heart disease.

参考文章(17)
Canner Pl, Berge Kg, Coronary drug project: experience with niacin. Coronary Drug Project Research Group. European Journal of Clinical Pharmacology. ,(1991)
Robert H. Knopp, Drug treatment of lipid disorders The New England Journal of Medicine. ,vol. 341, pp. 498- 511 ,(1999) , 10.1056/NEJM199908123410707
Henry N. Ginsberg, Penny Kris-Etherton, Barbara Dennis, Patricia J. Elmer, Abby Ershow, Michael Lefevre, Thomas Pearson, Paul Roheim, Rajasekhar Ramakrishnan, Roberta Reed, Kent Stewart, Paul Stewart, Katherine Phillips, Nancy Anderson, Effects of Reducing Dietary Saturated Fatty Acids on Plasma Lipids and Lipoproteins in Healthy Subjects The Delta Study, Protocol 1 Arteriosclerosis, Thrombosis, and Vascular Biology. ,vol. 18, pp. 441- 449 ,(1998) , 10.1161/01.ATV.18.3.441
Howard H Knapp, Helmut Schrott, Patrick Ma, Robert Knopp, Bruce Chin, J.Michael Gaziano, Joanne M Donovan, Steven K Burke, Michael H Davidson, Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia The American Journal of Medicine. ,vol. 110, pp. 352- 360 ,(2001) , 10.1016/S0002-9343(01)00638-6
Megan L. Wolfe, Sara F. Vartanian, Joyce L. Ross, Lori-Lynn Bansavich, Emile R. Mohler, Emma Meagher, Christopher A. Friedrich, Daniel J. Rader, Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. American Journal of Cardiology. ,vol. 87, pp. 476- 479 ,(2001) , 10.1016/S0002-9149(00)01410-7
Michael H. Davidson, Maureen A. Dillon, Bruce Gordon, Peter Jones, Julie Samuels, Stuart Weiss, Jonathon Isaacsohn, Phillip Toth, Steven K. Burke, Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. JAMA Internal Medicine. ,vol. 159, pp. 1893- 1900 ,(1999) , 10.1001/ARCHINTE.159.16.1893
Michel de Lorgeril, Patricia Salen, Jean-Louis Martin, Isabelle Monjaud, Jacques Delaye, Nicole Mamelle, Mediterranean Diet, Traditional Risk Factors, and the Rate of Cardiovascular Complications After Myocardial Infarction Final Report of the Lyon Diet Heart Study Circulation. ,vol. 99, pp. 779- 785 ,(1999) , 10.1161/01.CIR.99.6.779
Carolyn E. Walden, Barbara M. Retzlaff, Brenda L. Buck, Barbara S. McCann, Robert H. Knopp, Lipoprotein Lipid Response to the National Cholesterol Education Program Step II Diet by Hypercholesterolemic and Combined Hyperlipidemic Women and Men Arteriosclerosis, Thrombosis, and Vascular Biology. ,vol. 17, pp. 375- 382 ,(1997) , 10.1161/01.ATV.17.2.375
Melissa A Austin, John E Hokanson, Karen L Edwards, Hypertriglyceridemia as a cardiovascular risk factor. American Journal of Cardiology. ,vol. 81, pp. 7- 12 ,(1998) , 10.1016/S0002-9149(98)00031-9